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Abstract: Polo-like kinase 1, an important enzyme with diverse biological actions in  
cell mitosis, is a promising target for developing novel anticancer drugs. A combined 
molecular docking, structure-based pharmacophore modeling and three-dimensional 
quantitative structure-activity relationship (3D-QSAR) study was performed on a set of 
4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. The common 
substructure, molecular docking and pharmacophore-based alignment were used to develop 
different 3D-QSAR models. The comparative molecular field analysis (CoMFA) and 
comparative molecule similarity indices analysis (CoMSIA) models gave statistically 
significant results. These models showed good q
2 and r
2
pred values and revealed a good 
response to test set validation. All of the structural insights obtained from the 3D-QSAR 
contour maps are consistent with the available crystal structure of PLK1. The contour  
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maps obtained from the 3D-QSAR models in combination with the structure based 
pharmacophore model help to better interpret the structure-activity relationship. These 
satisfactory results may aid the design of novel PLK1 inhibitors. This is the first report on 
3D-QSAR study of PLK1 inhibitors. 
Keywords: PLK1; 3D-QSAR; pharmacophore; molecular docking 
 
1. Introduction 
Polo-like kinases (PLKs), a family of serine/threonine protein kinases, have attracted much 
attention as important elements that regulate cell cycle progression, particularly mitosis. In homo 
sapiens, four PLK homologs have been identified (PLK1, PLK2, PLK3 and PLK4) [1], and more 
recently, PLK5 has been identified. However, PLK5 is short of a kinase domain and may not function 
in cell cycle regulation [2]. They all share a highly conserved N-terminal catalytic kinase domain and a 
C-terminal region composed of “polo boxes” (only one in PLK4). PLK1 is the most investigated 
member of the family and has been widely considered as an anticancer target [3–5]. PLK1 is expressed 
primarily in dividing cells, which functions in mitosis entry, centrosome maturation, kinetochore 
assembly, bipolar spindle formation, cytokinesis and the exit of mitosis [6–13]. Knockdown or 
pharmacologic inhibition of PLK1 in tumor cells results in defects in centrosome maturation and 
separation, mitotic spindle formation and chromosome alignment, leading to disruption of cell mitosis 
and even apoptosis [14–16]. 
PLK1 is strongly associated with human malignancy due to its frequent over-expression in a variety 
of tumors with poor prognosis, such as breast cancer, ovarian cancer, pancreatic cancer, lung cancer, 
endometrial cancer, head and neck cancer, gastric cancer, prostatic cancer, etc. [4,17]. Given the 
oncogenic amplification and transforming potential of PLK1, there is a high level of interest and an 
increasing effort to inhibit its enzymatic activity with small-molecule compounds to the catalytic 
domain (ATP-binding site) for cancer therapy. Currently seven PLK1 inhibitors are in clinical trials 
and well tolerated in humans [18–20]. Recently, the 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline 
derivatives were reported as a novel class of PLK1 inhibitors, showing high potency at a nanomolar 
level [18,20,21]. Due to favorable biochemical profiles, high potency both in vivo and in vitro, and the 
acceptable oral bioavailability, two compounds of this class were subjected to clinical trials [18,20]. 
However, the study of type II PLK1 inhibitors is relatively slow. Only one case of potent type II 
inhibitors was reported by Keppner and coworkers in 2009 [22]. 
To date, there have not been any reports on 3D-QSAR studies of PLK1 inhibitors. Herein, we report 
the application of pharmacophore modeling, docking, comparative molecular field analysis (CoMFA) [23] 
and comparative molecular similarity analysis (CoMSIA) [24] 3D-QSAR methods to the 
4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives. This study was undertaken to gain insights 
into molecular mechanisms and structural requirements crucial for potential inhibition of PLK1, which 
could be useful in the design of novel PLK1 inhibitors. The CoMFA and CoMSIA analyses were 
conducted to investigate how the activity is influenced by steric, electrostatic, hydrophobic, and 
hydrogen bonding interactions. The 3D-QSAR models obtained from both the ligand- and Int. J. Mol. Sci. 2011, 12                 
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structure-based alignments were both found to be statistically valid in terms of the interpretation of 
interaction mode and the predictability to internal and external compounds. The contour plots obtained 
from the 3D-QSAR models correlated well, not only with the detailed interactions between the ligands 
and active-site residues in the crystal structures of PLK1, but also the pharmacophore features directly 
derived from the receptor-ligand interactions in crystal structures. The developed computational 
models are expected to help with better understanding of the QSAR of this class of compounds, as well 
as ensuring the researcher an in-depth analysis about the lead compounds for PLK1 inhibitor in further 
studies. To the best of our knowledge, this work will be the first 3D-QSAR study of PLK1  
inhibitors reported. 
2. Results and Discussion 
2.1. Multiple Structure Alignment Analyses 
The accuracy and reliability of the CoMFA and CoMSIA model is directly dependent on the 
structural alignment rule. Therefore, before PLS analyses to construct the 3D-QSAR models, we 
performed the structure and ligand based alignment to find the effective alignment to this dataset 
(Table 1). Because the alignments involved were actually based on the co-crystal structure of 
compound 73 with PLK1, a preliminary analysis on its binding mode was necessary. Figure 1 shows 
the co-crystal interaction mode of compound 73 with PLK1 (2YAC, resolution: 2.2 Å). The core of 
compound 73 is sandwiched between Phe183 at the bottom of the ATP binding pocket and Cys67 in 
the back of the G-loop. An aromatic ring stacking interaction is found between the Phe183 and 
compound  73, which has an important influence on the conformational equilibrium of the whole 
compound. The 4-methylpiperazinyl moiety penetrates to the solvent accessible region, which may be 
involved in hydrophilic interactions. The 2-hydroxyethyl group positions at the same place related to 
the ribose moiety of ATP, which is a site tolerant to the long chain substituent. In addition to two 
conservative hydrogen bonds formed with the hinge region residue Cys133, the amide moiety and the 
trifluoromethoxyl group are engaged in three and one hydrogen bonding interactions, respectively. The 
knowledge on binding mode will assist in the evaluation of compound alignments as well as QSAR analyses. 
Figure 1. The co-crystal binding mode of compound 73 with PLK1. The hydrogen bond is 
represented with red dotted line. 
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Table 1. Structures of 73 compounds. 
N
N
N N
R1
O
R
2
HN
R3
R
4  
Compound R
1 R
2 R
3 R
4 
1 *  NHMe Me  H  H 
2 *  NHcyclopropyl Me  H  H 
3  NHcyclopentyl Me  H  H 
4  NHPh Me  H  H 
5  NH2 Me CF3 H 
6  NH2 Ph  H  H 
7  NH2  i-Pr H  H 
8  NH2 1-methylpiperidine-4-yl H  H 
9  NH2 2-(piperidin-1-yl)-ethyl  H  H 
10*  NH2 Me  H  m-CF3 
11  NH2 Me  H  p-CF3 
12  NH2 Me Ac  H 
13  NH2 Me  H  m-Ac 
14  NH2 Me  OMe  H 
15  NH2 Me  H  m-OMe 
16  NH2 Me  H  p-OMe 
17  NH2 Me  NO2 H 
18  NH2 Me  H  m-NO2 
19  NH2 Me Me  H 
20 *  NH2 Me  NHMe  H 
21  NH2 Me i-Pr H 
22 *  NH2 Me  COOMe  H 
23 *  NH2 Me  CONH2 H 
24  NH2 Me  SO2NH2 H 
25  NH2 Me Ph  H 
26 *  NH2 Me  OPh  H 
27  NH2 Me  benzyl  H 
28 *  NH2 Me  NHPh  H 
29  NH2 Me  benzoyl  H 
30 *  NH2 Me  SPh  H 
31  NH2 Me Ac  3′-(4-methyl-piperazin-1-yl) 
32 *  NH2 Me Ac  4′-(4-methyl-piperazin-1-yl) 
33  NH2 Me Ac  5′-(4-methyl-piperazin-1-yl) 
34  NH2 Me  OMe  4′-(4-methyl-piperazin-1-yl) 
35 *  NH2 Me  OMe  5′-(4-methyl-piperazin-1-yl) 
36  OEt Me H  H 
37  NH2 Me  NH2 H 
38  NH2 Me  NHAc  H Int. J. Mol. Sci. 2011, 12                 
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Table 1. Cont. 
Compound R
1 R
2 R
3 R
4 
39  NH2 Me  OCF3 H 
40  NH2 Me  OCF3  5'
H
N
N
41 *  NH2 Me  OCF3  5'
H
N
N
42  NH2 Me  OCF3  5' N N
43  NH2 Me  OCF3  5'
N
H
NH
44  NH2 Me  OCF3  5' N NH
45  NH2 Me  OCF3 
5'
N
H
N N
O
NH
46 *  NH2 Trityl  OCF3  5' N N
47  NH2 H  OCF3  5' N N
48 *  NH2 2-Fluoro-ethyl  OCF3  5' N N
49  NH2 Ethyl  OCF3  5' N N
50 *  NH2 2-Methoxy-ethyl  OCF3  5' N N
51  NH2 2-Chloro-ethyl  OCF3  5' N N
52  NH2 Vinyl  OCF3  5' N N
53 *  NH2 Me  OCF3  5' N N
54  NH2 Me  OCF3 5 ′-NH2 
55  NH2 Me  OCF3  5' N
N
56 *  NH2 Me  OCF3  5' N N
57  NH2 Me  OCF3  5'
H
N
NInt. J. Mol. Sci. 2011, 12                 
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Table 1. Cont. 
Compound R
1 R
2 R
3 R
4 
58  NH2 Me  OCF3  5' N
59  NH2 Me  OCF3  5' N
60  NH2 Me  OCF3 
5' N N
OH
61  NH2 Me  OCF3 
5' N N
OH
62 *  NH2 Me  OCF3  5' N N N
63  NH2 Me  OCF3  5' N
N
64 *  NH2 Me  OCF3 
5'
N
H
N
N
65  NH2 Me  OCF3  5'
N
H
N
66 *  NH2 Me  OCF3  5'
N
H
N
H  
67  NH2 Me  OCF3  5'
N
H
O H
N
68  NH2 Me  OCF3  5'
N
H
O
N
69  NH2 –(CH2)3–N–(CH3)2 OCF3  5' N N
70 *  NH2 
O O
OCF3  5' N N
 
71  NH2 –(CH2)2–NH2 OCF3  5' N N
72  NH2 –(CH2)3–NH2 OCF3  5' N N
73  NH2 –(CH2)2–OH OCF3  5' N N
* Compounds in test set. 
As depicted in Figure 2, all 73 compounds were aligned well, using the common substructure based 
method. GLIDE performed quite well, as most conformations bind in a way analogous to the bound 
ligand of 2YAC, i.e., compound 73 (Figure 3). Thus, the alignment derived by GLIDE docking is Int. J. Mol. Sci. 2011, 12                 
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considered reasonable. Figure 4a,b illustrate two pharmacophore models deduced from the PLK1 
crystal structures 2YAC and 3KB7 by LigandScout. It is obvious that they share nearly identical 
features. To cover the most common features that may be required by PLK1 inhibitory potency, we 
clustered and subsequently merged them to a new pharmacophore model. This merged model  
(Figure 4c) consists of one hydrogen-bond acceptor, one hydrogen-bond donor, three hydrophobic and 
one ionizable positive, which is simplified by discarding three redundant hydrophobic features. Figure 4d 
shows the result of pharmacophore mapping of those compounds, which also suggests an   
excellent alignment. 
Figure 2. The common substructure based alignment. 
 
Figure 3. The resultant conformations from GLIDE docking. 
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Figure 4. (a) Pharmacophore model derived from 2YAC; (b) Pharmacophore model derived 
from 3KB7; (c) The merged model; (d) The compounds alignment based on the merged 
model. Features are color-coded with magenta for hydrogen-bond donor, green for 
hydrogen-bond acceptor, light-blue for hydrophobic, red for ionizable positive. 
   
   
Taken together, the results from common substructure and the merged pharmacophore based 
alignments, as well as GLIDE docking, proved to be reasonable and effective. It was difficult to judge 
which alignment would be more practicable, therefore, they were all subjected to the next step for 
model generation to further investigate their applicability and gain a more extensive insight to QSAR 
of pyrazoloquinazoline PLK1 inhibitors. 
2.2. CoMFA and CoMSIA Statistical Results 
Owing to the fact that common substructure, GLIDE docking and the pharmacophore methods all 
produced acceptable alignments of 73 known PLK1 inhibitors, the corresponding CoMFA and 
CoMSIA analyses were performed independently for further comparison. The statistical results of PLS 
analyses for CoMFA and CoMSIA studies are listed in Table 2. The pharmacophore based model 
yielded q
2 = 0.628 and r
2 = 0.941 for CoMFA, whereas the GLIDE docking and common substructure 
based model produced a lower q
2 value of 0.283 and 0.578, and r
2 value of 0.420 and 0.867 for 
CoMFA, respectively. Multiple CoMSIA models were derived based on three types of alignment, with 
various combinations of steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond 
acceptor fields. To get a clear view, only parameters of models whose q
2 value are higher than those of 
other models derived from the same alignment were considered. It is obvious that CoMSIA models Int. J. Mol. Sci. 2011, 12                 
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from common substructure, GLIDE docking and pharmacophore based alignments showed 
comparable results. The inhibitory activities (pIC50), the predicted activities using the CoMFA and 
CoMSIA models, and the corresponding residual values for the training set compounds are listed in 
Tables 3 and 4. Graphic representations of experimental vs. predicted inhibitory activity of training set 
for pharmacophore-based CoMFA and typical CoMSIA models are shown in Figure 5. In all, the 
CoMFA and CoMSIA models we constructed possess high q
2 and r
2 value, indicating that they have 
good internal predictive ability and that results were not based on any chance correlation. To validate 
both the predictability and accuracy of the models for external compounds, the predictive correlation 
coefficient  r
2
pred was calculated for the test set. As shown in Tables 3 and 4, the r
2
pred value of 
pharmacophore-based CoMFA model and CoMSIA models spans from 0.605 to 0.827 and most of the 
residual values are less than 1.0, revealing that the models are highly reliable and can be used to 
predict the biological activities of novel compounds; whereas, the r
2
pred value of CoMFA models from 
GLIDE docking and common substructure based alignment is somehow lower, reflecting poor 
predictive ability. The plots of experimental vs. predicted inhibitory activity of test set for CoMFA and 
CoMSIA models are shown in Figure 5, showing that the predicted activities were in good agreement 
with the original data and the reliable CoMFA and CoMSIA models have a robust external predictive ability. 
It can be concluded easily that the best model for CoMFA was obtained from the 
pharmacophore-based method (model 2) while it was difficult to distinguish the best CoMSIA model 
because there is no significant difference between PLS statistical results. Hence, we have paid 
attention to all CoMSIA models (models 4, 5 and 6), considering the representation of different fields, 
the satisfactory internal and external predictive ability in terms of q
2 and r
2
pred value, respectively. 
Table 2. Statistics summary of CoMFA and CoMSIA models. 
Alignment Method 
CoMFA Model  CoMSIA Model 
GD 
a PH 
b CS 
c GD  PH  CS 
No. 1  2  3  4  5  6 
q
2 0.283  0.628  0.578  0.574  0.532  0.588 
r
2 0.42  0.941  0.867  0.97  0.859  0.834 
SEE 
d 0.818  0.268  0.404  0.198  0.411  0.447 
F 
e 36.929  192.635  78.313  207.094  99.622  81.965 
ONC 
f 1  4  4  7  3  3 
Field analysis           
Steric 0.663  0.619  0.698  0.177  0.224  0.263 
Electrostatic 0.337  0.381  0.618  0.52 0.407  0.459 
Hydrophobic -  -  -  -  -  - 
H-bond donor  -  -  -  0.303  0.369  0.277 
H-bond acceptor  -  -  -  -  -  - 
Test set             
r
2
pred 
g 0.405  0.785  0.752  0.605  0.695  0.749 
a Glide docking; 
b Pharmacophore; 
c Common substructure; 
d Standard estimated error; 
e Fisher value;  
f Optimal number of components; 
g Predictive correlation coefficient for test set. Int. J. Mol. Sci. 2011, 12                 
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Table 3. The experimental pIC50, predicted pIC50 and residual values of all compounds 
derived from the CoMFA models. 
Compound pIC50 
Model 1  Model 2  Model 3 
Prediction Residue Prediction Residue Prediction Residue
1 *  5.375  5.848  −0.473 5.227  0.148  5.380 −0.005 
2 *  5.000  5.934  −0.934 5.406 −0.406 5.063 −0.063 
3 5.000  5.824  −0.824 5.228 −0.228 4.778 0.222 
4 5.000  5.724  −0.724 4.795  0.205  5.298 −0.298 
5 6.365  6.544  −0.180 6.382 −0.018 6.282 0.082 
6 5.000  6.101  −1.101 5.591 −0.591 5.653 −0.653 
7  6.367 6.074 0.293 5.935 0.432 5.765 0.602 
8 5.000  6.394  −1.394 5.096 −0.096 4.798 0.202 
9 5.000  6.543  −1.543 4.966  0.034  5.060 −0.060 
10 *  7.292  6.249  1.043  7.358  −0.066 6.423 0.869 
11 6.060  5.547  0.513  6.153  −0.093 6.165 −0.106 
12 6.461  6.536  −0.075 6.401  0.060  6.286 0.175 
13 7.000  5.914  1.086  7.105  −0.105 6.575 0.425 
14  7.377 6.378 0.999 7.359 0.018 7.120 0.257 
15  6.870 6.068 0.802 6.798 0.072 6.649 0.221 
16  6.592 5.970 0.622 6.402 0.190 6.886  −0.294 
17 6.312  6.354  −0.042 6.395 −0.083 6.125 0.187 
18 5.000  5.892  −0.892 5.074 −0.074 6.189 −1.189 
19  7.824 6.040 1.784 7.420 0.404 6.858 0.966 
20  *  6.959 6.260 0.699 6.240 0.719 7.193  −0.234 
21 6.438  6.216  0.222  6.485  −0.047 6.749 −0.311 
22 *  5.952  6.490  −0.538 6.844 −0.892 6.745 −0.793 
23 *  5.683  6.250  −0.567 5.481  0.202  6.781 −1.098 
24 5.428  6.150  −0.722 5.564 −0.136 6.110 −0.682 
25 5.806  6.316  −0.511 6.198 −0.393 6.044 −0.238 
26 *  6.556  6.624  −0.068 6.279  0.277  6.216 0.340 
27 6.026  6.216  −0.191 6.005  0.021  6.035 −0.010 
28 *  6.023  6.609  −0.586 6.150 −0.127 6.212 −0.189 
29 5.706  6.380  −0.674 5.686  0.020  5.724 −0.018 
30 *  5.692  6.772  −1.080 6.168 −0.476 6.094 −0.402 
31 5.688  5.964  −0.276 5.904 −0.216 5.913 −0.225 
32 *  6.334  6.768  −0.435 5.746  0.587  7.694 −1.361 
33 6.963  7.711  −0.748 7.152 −0.189 6.698 0.265 
34 7.398  6.327  1.071  7.573  −0.175 7.330 0.068 
35 *  8.155  7.441  0.714  8.503  −0.348 8.226 −0.071 
36 5.000  5.874  −0.874 5.070 −0.070 5.195 −0.195 
37 6.824  6.153  0.671  6.920  −0.096 6.796 0.028 
38 5.598  5.973  −0.375 5.145  0.453  5.588 0.010 
39  6.932 6.387 0.545 6.681 0.251 6.716 0.216 
40 6.016  7.373  −1.357 6.026 −0.010 5.755 0.261 
41 *  6.910  7.384  −0.474 6.320  0.590  7.188 −0.278 
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Table 3. Cont. 
Compound pIC50 
Model 1  Model 2  Model 3 
Prediction Residue Prediction Residue Prediction Residue
42 8.097  7.501  0.596  8.130  −0.033 8.653 −0.556 
43 7.114  7.318  −0.204 7.163 −0.050 7.056 0.058 
44  8.699 7.428 1.271 8.567 0.132 8.275 0.424 
45 7.456  7.522  −0.066 7.163  0.293  7.905 −0.449 
46 *  5.000  7.379  −2.379 5.528 −0.528 4.123 0.877 
47  8.398 7.156 1.242 8.361 0.037 8.363 0.035 
48  *  8.398 7.276 1.122 7.868 0.530 8.064 0.334 
49  8.222 7.609 0.613 7.959 0.263 8.069 0.153 
50  *  7.824 7.300 0.524 7.527 0.297 7.675 0.149 
51  8.155 7.316 0.839 8.152 0.003 7.918 0.237 
52 8.222  7.518  0.704  8.339  −0.117 8.073 0.149 
53  *  8.523 7.555 0.968 8.221 0.302 8.579  −0.056 
54 7.222  6.432  0.790  7.500  −0.278 7.182 0.040 
55 7.602  7.416  0.186  7.967  −0.365 7.685 −0.083 
56  *  7.482 7.453 0.028 6.750 0.732 8.656  −1.175 
57 6.699  7.505  −0.806 7.303 −0.604 6.568 0.131 
58  8.523 7.497 1.026 8.082 0.441 8.499 0.024 
59  8.222 7.333 0.889 8.070 0.152 8.018 0.204 
60 6.813  7.516  −0.704 6.580  0.233  7.415 −0.603 
61 6.697  7.502  −0.805 6.439  0.258  7.358 −0.661 
62 *  7.377  7.417  −0.040 7.465 −0.088 7.735 −0.358 
63 7.222  7.129  0.093  7.568  −0.346 6.608 0.614 
64 *  6.975  7.354  −0.379 6.220  0.755  7.077 −0.102 
65 6.827  7.660  −0.833 6.591  0.236  7.034 −0.207 
66 *  7.081  7.358  −0.277 6.546  0.535  6.968 0.113 
67 7.357  7.555  −0.199 7.285  0.071  6.833 0.523 
68 6.650  7.634  −0.984 6.181  0.469  6.117 0.533 
69 6.554  7.291  −0.737 6.763 −0.209 6.665 −0.111 
70 *  7.367  7.521  −0.155 6.587  0.780  7.756 −0.390 
71 7.482  7.562  −0.081 8.013 −0.532 7.765 −0.284 
72 7.284  7.647  −0.363 7.332 −0.048 7.703 −0.419 
73  8.699 7.541 1.158 8.292 0.407 8.235 0.464 
* Test set compounds. Int. J. Mol. Sci. 2011, 12                 
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Figure 5. Plot of predicted vs. experimental values of (a) CoMFA model 2 and (b) CoMSIA 
models 4, 5 and 6. 
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Table 4. The experimental pIC50, predicted pIC50 and residual values of all compounds 
derived from the CoMSIA models. 
Compound pIC50
Model 4  Model 5  Model 6 
Prediction Residue Prediction Residue Prediction Residue
1  *  5.375 5.171 0.204 5.208 0.167 4.833 0.542 
2 *  5.000 5.524  −0.524 5.168 −0.168 4.781  0.219 
3 5.000 5.037  −0.037 5.159 −0.159 4.620  0.380 
4 5.000 5.099  −0.099 5.024 −0.024 5.314 −0.314 
5  6.365 6.248 0.116 6.307 0.057 6.225 0.140 
6 5.000 4.967  0.033  5.446  −0.446 5.907 −0.907 
7  6.367 6.230 0.137 5.931 0.436 5.911 0.456 
8 5.000 5.102  −0.102 5.189 −0.189 4.950  0.050 
9 5.000 5.239  −0.239 5.014 −0.014 5.194 −0.194 
10  * 7.292 6.092 1.200 6.508 0.784 6.233 1.059 
11 6.060 6.063  −0.003  5.964 0.095 6.148  −0.088 
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Table 4. Cont. 
Compound pIC50 
Model 4  Model 5  Model 6 
Prediction Residue Prediction Residue  Prediction  Residue 
12 6.461  6.453  0.008  6.401  0.060  6.052  0.409 
13 7.000  7.012  −0.012 6.302  0.698  6.818  0.182 
14 7.377  7.070  0.307  7.380  −0.003 6.911  0.466 
15 6.870  7.040  −0.170 6.452  0.418  6.517  0.353 
16 6.592  6.660  −0.068 6.576  0.016  6.926  −0.334 
17 6.312  6.395  −0.083 6.653 −0.341 6.169  0.143 
18 5.000  5.062  −0.062 5.449 −0.449 5.846 −0.846 
19 7.824  7.011  0.813  6.951  0.873  6.576  1.248 
20 *  6.959  6.528  0.431  5.916  1.043  6.666  0.293 
21 6.438  6.699  −0.261 6.742 −0.304 6.645 −0.207 
22 *  5.952  6.461  −0.509 6.993 −1.041 6.700 −0.748 
23 *  5.683  5.490  0.193  5.590  0.093  6.630  −0.947 
24 5.428  5.327  0.101  5.574  −0.146 5.521 −0.093 
25 5.806  5.896  −0.090 6.583 −0.778 6.265 −0.459 
26 *  6.556  5.894  0.662  6.111  0.445  6.740  −0.184 
27 6.026  5.814  0.212  6.347  −0.322 6.295 −0.270 
28 *  6.023  5.744  0.279  6.477  −0.454 6.749 −0.726 
29 5.706  5.708  −0.002 5.322  0.384  6.148  −0.442 
30 *  5.692  6.086  −0.394 6.111 −0.419 6.328 −0.636 
31 5.688  5.601  0.087  6.117  −0.429 6.026 −0.338 
32 *  6.334  8.044  −1.711 6.289  0.045  7.253  −0.920 
33 6.963  6.937  0.026  6.742  0.221  6.561  0.402 
34 7.398  7.349  0.049  7.880  −0.482 7.183  0.215 
35 *  8.155  7.191  0.964  7.979  0.176  8.207  −0.052 
36 5.000  5.047  −0.047 4.871  0.129  5.260  −0.260 
37 6.824  6.803  0.021  6.603  0.221  7.167  −0.343 
38 5.598  5.651  −0.053 5.731 −0.133 5.382  0.216 
39 6.932  7.623  −0.691 6.973 −0.041 6.569  0.363 
40 6.016  6.033  −0.017 6.427 −0.411 5.770  0.246 
41 *  6.910  6.012  0.898  6.753  0.157  7.180  −0.270 
42 8.097  8.147  −0.050 8.069  0.028  8.308  −0.211 
43 7.114  7.115  −0.002 6.944  0.170  6.619  0.495 
44 8.699  8.774  −0.075 8.472  0.227  8.358  0.341 
45 7.456  7.337  0.119  6.944  0.512  7.701  −0.245 
46 *  5.000  5.778  −0.778 5.855 −0.855 4.419  0.581 
47 8.398  8.364  0.034  8.644  −0.246 8.514 −0.116 
48 *  8.398  8.319  0.079  8.168  0.230  7.910  0.488 
49 8.222  8.041  0.181  7.951  0.271  7.944  0.278 
50 *  7.824  7.912  −0.088 7.834 −0.010 7.619  0.205 
51 8.155  8.241  −0.086 7.889  0.266  7.766  0.389 
52 8.222  8.378  −0.156 8.125  0.097  7.931  0.291 
53 *  8.523  8.002  0.521  8.126  0.397  8.239  0.284 
54 7.222  7.369  −0.147 7.428 −0.206 7.069  0.153 Int. J. Mol. Sci. 2011, 12                 
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Table 4. Cont. 
Compound pIC50 
Model 4  Model 5  Model 6 
Prediction Residue Prediction Residue  Prediction  Residue 
55 7.602  7.615  −0.013 8.039 −0.437 7.530  0.072 
56 *  7.482  7.503  −0.022 7.064  0.418  8.246  −0.765 
57 6.699  6.573  0.126  6.999  −0.300 6.315  0.384 
58 8.523  8.441  0.082  7.866  0.657  8.501  0.022 
59 8.222  8.102  0.120  8.128  0.094  7.886  0.336 
60 6.813  6.696  0.117  6.928  −0.116 7.765 −0.953 
61 6.697  6.888  −0.191 6.960 −0.263 7.513 −0.816 
62 *  7.377  7.339  0.038  7.754  −0.377 7.886 −0.509 
63 7.222  7.253  −0.031 7.863 −0.641 6.816  0.406 
64 *  6.975  6.454  0.521  5.790  1.185  7.407  −0.432 
65 6.827  6.790  0.037  6.234  0.593  7.473  −0.646 
66 *  7.081  6.289  0.792  6.296  0.785  7.145  −0.064 
67 7.357  7.293  0.063  6.725  0.632  6.899  0.458 
68 6.650  6.515  0.135  6.238  0.412  6.724  −0.074 
69 6.554  6.540  0.014  7.249  −0.695 7.200 −0.646 
70 *  7.367  6.809  0.558  6.531  0.836  7.257  0.110 
71 7.482  7.571  −0.090 7.993 −0.512 7.728 −0.247 
72 7.284  7.357  −0.073 7.314 −0.030 7.624 −0.340 
73 8.699  8.680  0.019  7.805  0.894  8.294  0.405 
* Test set compounds. 
2.3. CoMFA Contour Maps 
The results of CoMFA analyses from pharmacophore-based alignment (model 2) are displayed as 
color-coded contours, allowing visual inspection of regions responsible for favorable or unfavorable 
interactions with PLK1. The green contours indicate regions where bulky substitution enhances 
binding affinity, and the yellow contours suggest regions where bulky substitution reduces the binding 
affinity. In the electrostatic interaction map, the blue contours indicate regions where more positively 
charged substituents are favored and the red contours suggest regions where more negatively charged 
substituents are favored. The favorable and unfavorable contributions of both fields were plotted as 
default proportion (80:20). Since the QSAR models were developed based on the information from 
receptor (docking, structure-based pharmacophore and common substructure from crystal bound 
conformation), the contour maps produced by CoMFA and CoMSIA could be superimposed onto the 
PLK1 structure. Thus, to get a straightforward insight into the steric and electrostatic interaction 
between compounds and PLK1, we introduced the van der waals surface or electrostatic potential 
surface of protein as background. 
The steric and electrostatic fields contribute to 61.9% and 38.1% of the variance, respectively. The 
steric contour map is shown in Figure 6a with one of the most potent inhibitors, i.e., compound 73 as a 
reference. A moderate green contour is seen in proximity to the o-trifluoromethoxyl group of phenyl 
ring, but sandwiched by the protein surface, suggesting that only the medium-sized substituent is 
favored at this position such as methoxyl, trifluoromethoxyl, and methyl. The large green contours are Int. J. Mol. Sci. 2011, 12                 
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found around the 4-methylpiperazinyl moiety at 5′ position of the phenyl ring, which penetrate to the 
solvent accessible region. This indicates that diverse substituents with bulky size at 5′ position of the 
phenyl ring are favorable to activity and their orientations are tolerable in space, except those 
extending to the upper side. Those situations for steric favorable substituents are the same for 
compounds 35, 42, 44, 47, 48, 51, 53, 58 and 59, all of which show better activity (below 10 nM) and 
have moderate and bulky groups at 3′ and 5′ positions of the phenyl ring. However, compounds that 
have only one steric favorable site show only moderate binding affinity, e.g., compounds 5, 12, 14, 15, 
22, 25, 28, 29, 38 and 33, demonstrating that both sites are indispensable. The emergence of yellow 
contours in the front of 2-hydroxyethyl group suggests that a more bulky substituent at position 1 of 
pyrazole ring would lower the activity. For example, replacement of 2-hydroxyethyl group with longer 
substituents (compounds 69, 70 and 72) led to a significant reduction of potency. Another yellow 
contour over the phenyl ring shows that a bulky substituent in this area is not favorable; but when the 
phenyl ring is flipped vertically by ~90 °, this area can also be occupied by substituents, such as 
compounds 11, 16, 21, 27, 30 and so on. In all, there is a definite requirement of an appropriate shape 
to exhibit high potency when designing novel PLK1 inhibitors, and thus it is important to pay attention 
to the steric characteristics. 
Figure 6. The CoMFA contour map of model 2 combined with compound 73. (a) Steric 
field distribution on the background of protein surface; and (b) electrostatic field distribution 
on the background of electrostatic potential surface colored from purple to red owing to the 
increase of electron density. Green contours indicate regions where bulky groups increase 
activity, whereas yellow contours indicate regions where bulky groups decrease activity. 
Red contours suggest negative charge favoring activity, whereas blue contours suggest 
positive charge favoring activity. 
  
Electrostatic contour maps are also shown with compound 73 as a reference (Figure 6b). In general, 
red contour maps are close to heteroatoms such as nitrogen and oxygen, whose partial atomic charges 
are highly negative. Two main red contours are found close to 4-methylpiperazinyl moiety, of which N 
atoms bear negative charges, indicating negative potential is preferred in these areas. This trend can be 
reflected in the activities of compounds 35, 44, 47, 48, 49, 51, 52, 53, 58, 59 and 73, which all have 
tertiary amine substructures. Confusingly, the simple replacements of 4-methylpiperazinyl moiety with 
other tertiary amines for compound 53, either open-chain or cyclic, result in decreased potency against 
PLK1 from 10-fold to more than 300-fold, for compounds 40, 41, 43, 56, 57, 60, 61, 62, 63, 64, 65 and 68. 
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This can be explained by taking the steric factor into account, that an unfavorable steric contour exists 
over the 4-methylpiperazinyl moiety as illustrated in Figure 6a. With respect to the favorable positive 
potential, the blue contours are distributed around the o-trifluoromethoxyl group, 2-hydroxyethyl 
group and amide moiety, where the negative charge of protein surface is concentrated, suggesting that 
positive charged groups such as substituents with electron-withdrawing atoms increase the activity 
compared to the hydrogen atom. This is consistent with the increase of potency for compound 53 as 
compared to compound 35, due to the replacement of hydrogen atom with fluorine atom. A similar 
situation can be observed between compounds 71 and 73, for which the replacement of nitrogen atom 
with oxygen atom leads to increased activity. Besides, two small blue regions close to the amide 
moiety also represent the preferred electrostatic interaction around there, indicating that decreasing the 
electron-withdrawing effect would cause a reduction of binding affinity, such as compounds 1, 2, 3, 4 
and 36. Collectively, the distribution of electrostatic contours is well corroborated with the electrostatic 
potential information of the PLK1 active site, demonstrating its rationality. 
2.4. CoMSIA Contour Maps 
The CoMSIA contour maps of four models (models 4, 5 and 6), based on different alignment 
methods or combinations of various fields, are shown in Figure 7, which are depicted with compound 73 as 
the default from nearly the same viewpoint for a convenient comparison and analysis. The steric and 
electrostatic contours are colored identically with CoMFA contours map. In addition, the hydrophobic 
interactions are shown by yellow and white contours, whereas hydrogen bond donor interactions are 
represented by cyan and purple contours, indicating their favorable and unfavorable regions. The 
contributions of fields to the variance are listed in Table 2. It is evidenced that the electrostatic field 
contributes about 1.7–3 times more than the steric field, which is the opposite of corresponding 
relationships in the CoMFA models. As the alignment results are identical for CoMFA and CoMSIA 
models, this discrepancy may be explained by the different implementations of the fields for CoMFA 
and CoMSIA. Thus, we assume that both steric and electrostatic fields play important roles in the 
binding affinity and should be given equal attention. 
Since the steric and electrostatic interactions have been discussed above in detail, a critical eye has 
been given to the comparison of the contour distributions. As shown in Figure 7a–c, the green contours 
mainly concentrate around the 4-methylpiperazinyl moiety and the trifluoromethoxyl group, denoting 
that the bulky substituents are indeed favorable to these regions; a large yellow contour is constantly 
located between the 2-hydroxyethyl group and 4-methylpiperazinyl moiety, suggesting a potential 
steric clash may exist between those two substituents. However, there is a distinct difference in the 
steric contour above the 2-hydroxyethyl group as the green contour in model 4 is conversely yellow in 
model 6. It can be found that a small sub-pocket is positioned over the 2-hydroxyethyl group, which 
means bulky substituents are not acceptable, such as 2-(tetrahydro-2H-pyran-2-yloxy)-ethyl and 
3-aminopropyl groups, leading to lower binding affinities for compounds 70 and 72, respectively. 
Therefore, we conclude that a small yellow contour is more appropriate in that position. As for the 
electrostatic field, it can be observed that the contours of CoMSIA models are more concentrated 
around the 2-hydroxyethyl group and 4-methylpiperazinyl moiety (Figures 7d–f) in comparison with 
those of CoMFA model. In spite of this, common characteristics still exist. Commensurate with the Int. J. Mol. Sci. 2011, 12                 
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CoMFA model, in all three CoMSIA models, a blue contour and large red contour are close to the 
trifluoromethoxyl group and the 4-methylpiperazinyl moiety, respectively, denoting the electrostatic 
nature of those two positions are authentically reflected. In addition, a middle-sized blue contour is 
also proximate to 4-methylpiperazinyl moiety in the CoMSIA model derived from common 
substructure based method (model 6). Since the most frequently used substituents at position 5′ of 
phenyl ring are various tertiary amines, the blue contour may account for the electron-deficient 
methylenes. Therefore, the substituents at position 5′ of the phenyl ring should consist of the 
electron-withdrawing atom and the electron-deficient atom simultaneously rather than solely the 
electron-withdrawing atom, such as carbamoyl or sulfoamino group. This conclusion is supported by 
the fact that the position 5′ of phenyl ring is oriented to the solvent accessible region of PLK1 and the 
substituents with the ionizable groups at that position will be ionized in the solution, stabilizing 
interaction and enhancing potency. 
Areas favored by hydrogen bond donors are shown in cyan and magenta, respectively (Figures 7g–i). 
For all three CoMSIA models, two cyan contours are equidistant and close to the amino group of the 
amide moiety, mirroring the potency of two hydrogen atoms in the NH2 group to form hydrogen bonds 
with the residues of receptor in the corresponding orientations, such as Asp194. These contours can be 
associated with the increment in activity when the NH group of the amide moiety changes from 
ethoxyl and substituted amino groups in compounds 1, 2, 3, 4 and 36, implying the NH group plays a 
major role in binding to the PLK1 active sites. The purple contours are found in common around the 
4-methylpiperazinyl moiety, denoting the disadvantage of the hydrogen bond donor at this position for 
activity. This is corroborated with the distribution of electrostatic contours. A small purple contour is 
shown near the trifluoromethoxyl group that formed a hydrogen bond with the backbone NH group of 
Arg136 in our models and the guanidine NH group of Arg57 in PLK1 crystal structure (2YAC), 
respectively. Thus, the hydrogen bond acceptors at this position are favorable. A confusing purple 
contour is observed near the NH group of the amide moiety. As a crystal structure, and our models 
confirm the favor of the hydrogen bond donor at this area, this contour cannot be associated to the NH 
group. From a systematic investigation of the conformations superimposed with contours, we found 
the substituents at position 1 of pyrazole of compounds 69 and 72 might account for that purple 
contour, whose hydrogen bond donor groups reach this point due to the flexibility of the alkyl chain. Int. J. Mol. Sci. 2011, 12                 
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Figure 7. The CoMSIA contour map combined with compound 73. Steric field distribution 
for (a) model 4, (b) model 5 and (c) model 6, on the background of protein surface. 
Electrostatic field distribution for (d) model 4, (e) model 5, and (f) model 6, on the 
background of electrostatic potential surface colored from purple to red owing to the 
increase of electron density. Hydrogen bond donor field distribution for (g) model 4, 
(h) model 5 and (i) model 6. Green contours indicate regions where bulky groups increase 
activity, whereas yellow contours indicate regions where bulky groups decrease activity. 
Positive potential favored areas are in blue, and positive potential unfavored areas are in red. 
Cyan and purple contours indicate favorable and unfavorable hydrogen bond donor group. 
The hydrogen bond is represented with orange dotted line. 
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Figure 7. Cont. 
  
 
2.5. Comparison of Pharmacophore Model and CoMSIA Model 
Considering that the pharmacophore model we have constructed also consists of hydrogen bond 
related features and a hydrophobic feature, it would be significant to compare it with the CoMSIA 
models. Hence, the merged pharmacophore model was reproduced using Unity module in SYBYL 6.9 [25]. 
The graphical interpretation of the superimposition of the features and contours reflecting the 
hydrophobic and hydrogen bond donor fields is shown in Figure 8 with compound 73 as a reference. 
The contours reflect the corresponding fields of model 6 (derived from pharmacophore-based alignment). 
Two large green contours are close to two hydrophobic features located at the trifluoromethoxyl group 
and in the vicinity of the phenyl ring, suggesting bulky and hydrophobic substituents at these positions 
are favorable (Figure 8a). The ionizable positive feature is covered by the large red contour, indicating 
a hydrophilic characteristic is preferred here (Figure 8b). The hydrogen bond donor and acceptor 
features do not intersect with the contours related to the hydrogen bond donor field (Figure 8c). 
Despite only partial pharmacophore features overlapping well with corresponding contours, it is still 
considered reasonable because the features not overlapped with contours belong to the maximum 
common substructure of compounds or are conservative in most compounds used in this study, while 
the CoMSIA method mainly focuses on the variable parts for a class of compounds. In this sense, our 
3D-QSAR model and pharmacophore model complement each other well in elaborating the interaction 
mode of compound. 
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Figure 8. The pharmacophore model superimposed with (a) steric; (b) electrostatic and  
(c) hydrogen bond donor and acceptor contours of model 6. The pharmacophore features 
are colored the same as in Figure 4. The contours are depicted as mesh. 
   
 
2.6. Structural Insights from 3D-QSAR and Pharmacophore Studies 
Our analyses found that the electrostatic, steric and hydrogen bond donor characteristics are highly 
desirable for potent inhibitory activity. The contour maps show that a moderate bulky substituent with 
hydrogen bond donor at position 3 of pyrazole ring (R
1), a moderately bulky and hydrophobic group 
with electron-withdrawing heteroatom at position 2′ of phenyl ring (R
3), and a bulky and amphoteric 
substituent with both hydrophilic and hydrophobic moieties at position 5′ of phenyl ring (R
4), can play 
important roles in enhancing binding affinity. Moreover, the length of alkyl chain for the substituent at 
position 1 of pyrazole ring (R
2) should be no more than three carbon atoms. In addition, two hydrogen 
bonds formed between compounds and Cys133 in hinge region are important which can induce the 
conformation of the whole compound in the ATP pocket. Thus, influencing these two hydrogen bonds 
should be avoided when changing substituents at other positions. These insights are consistent with the 
structural features of ATP pocket, further indicating that our 3D-QSAR models are reasonable. As 
depicted in Figure 9, R
2 and R
4 groups project into the solvent accessible region, thus allowing a larger 
extent of variability for the steric, electrostatic and other properties of substituents. Nevertheless, the 
steric clashes between R
2 and R
4 groups should be avoided. Moreover, R
2 and R
4 groups still have an 
impact on PLK1 selectivity. The reasonable combinations of substituents at these two positions can 
increase the selectivity of PLK1 against PLK2-3 up to 5000 times. Although R
1 group can form 
hydrogen bonds with a water molecule, substituents that discard this interaction may also be positive to 
the enhancement of binding affinity and target selectivity. This is concluded from the study of Int. J. Mol. Sci. 2011, 12                 
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Fernandez and coworkers, which indicated that sculpting the shifting hydration patterns of the target 
would stabilize the protein surface and avoid disfavored induced fit [26]. 
Figure 9. Schematic representation for the SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline 
derivatives as PLK1 inhibitors. R
1: medium-sized substituent with hydrogen bond donor 
and acceptor; R
2: open-chain alkyl group with less than three carbon atoms or 
unsubstituted hydrogen; R
3: hydrophobic group with small size and strong 
electron-withdrawing atom, especially hydrogen bond acceptor; R
4: bulky substituents 
simultaneously with hydrophobic and hydrophilic moiety. 
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3. Materials and Methods 
3.1. Dataset 
All compounds used in the present study were taken from the literature [18,20,21]. Of the 73 
compounds, 52 ones (unasterisked in Table 1) were selected randomly as training set for model 
construction and the remaining 21 ones (asterisked in Table 1) were used as test set for model 
validation, according to biological activity range and structural diversity. The IC50 values of all 
compounds for PLK1 inhibition were normalized and converted to the logarithm unit of molar grade 
(pIC50 = −log IC50), which spanned 4 orders of magnitude (5.00–8.70). The distribution of activity data 
and the number of compounds were shown in Figure 10 to confirm with the test set as a true 
representative of the training set. Int. J. Mol. Sci. 2011, 12                 
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Figure 10. Distribution of activities (pIC50) for the training set and the test set versus 
numbers of compounds. The training set and the test set are colored as red and blue, respectively. 
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The X-ray crystal structures of this class of compounds bound with PDK1 are available from the 
protein data bank (PDB). The bound conformation of compound 73 (PDB code: 2YAC) [18] was used 
as a template to build the 3D structures for both training and test set compounds. The partial charge 
was calculated with Gasteiger-Hückel method. The common structure was constraint for each compound 
and only the varying parts were energy minimized by using conjugate gradient method and Tripos 
force field until an energy gradient of 0.05 kcal/mol was reached. These works were all done  
in SYBYL 6.9. 
3.2. Conformational Alignment 
Structure alignment is considered as an important and critical step in CoMFA and CoMSIA 
analyses because this affects the reliability of the models. In order to avoid bias towards a particular 
alignment method, the structure-based and ligand-based alignments were both used in this study.  
It should be noted that a study that specifically seeks to understand the influence of alignment methods 
on the predictive performance of 3D-QSAR model is an important direction but extended in the work 
presented here. Herein, the common substructure, molecular docking and pharmacophore-based 
alignment were performed to build the 3D-QSAR models. Meanwhile, the docking and pharmacophore 
studies would also provide beneficial insight into ligand-receptor interactions to help better understand 
the structure-activity relationship. 
3.2.1. Common Substructure Based Alignment 
The key assumptions of CoMFA and CoMSIA are that compounds with common substructure 
always adopt a similar conformation when binding with the target and the common substructure in 
each compound contributes equally. Therefore, we selected the co-crystal structure of compound 73 
from 2YAC as the template to align the remaining compounds using the “align database” command in 
SYBYL 6.9. The common substructure used for the alignment is shown in Figure 11. Int. J. Mol. Sci. 2011, 12                 
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Figure 11. The most common substructure used in common substructure-based alignment. 
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3.2.2. Molecular Docking Based Alignment 
Molecular docking was carried out to obtain reasonable molecular alignments for developing 
receptor-based 3D-QSAR models. At the beginning, we tested the applicability of three well-known 
docking software, viz. CDOCKER [27,28] in Discovery Studio 2.5, GOLD 5.0 [29,30] and GLIDE 4.5 
[31,32] in Maestro 8.0, by checking if the conformation of the bound ligand in PLK1 crystal structure 
can be reproduced, and whether the common substructure of all compounds in both training and test 
sets can overlap well with each other in a way analogous to the bound ligand in PLK1 crystal structure. 
Docking conformations output by both CDOCKER and GOLD overlapped in a chaotic state, 
suggesting a failure of alignment. In contrast, GLIDE performed quite well. Thus, GLIDE was 
eventually selected as the docking tool. 
The 3D structure of PLK1 (2YAC) in docking study was downloaded from Protein Data Bank. For 
GLIDE, the PDB structure was prepared using the “protein prepare wizard” automatically and 
subsequently its grid file was generated in Maestro 8.0. The initial conformation of compound used 
was obtained by conformational search in water with force filed of OPLS_2005 based on mixed 
torsional/low-mode sampling method in Maestro 8.0. The binding site was defined by the co-crystal 
ligand (compound 73) itself for all three docking software. The XP mode (extra precision) was 
selected and post-docking minimization was conducted to penalize highly strained ligand geometries 
and eliminate poses with eclipsing interactions. Finally, other options not mentioned above were kept 
as default. 
3.2.3. Pharmacophore Based Alignment 
The structure based pharmacophore model can be derived directly from ligand-protein co-crystal 
structure and thus can reflect more reliable combination of the essential features required for the 
relating biological potency [33]. As the compounds used in 3D-QSAR analyses belong to the same 
class and the co-crystal structures of PLK1 are available, the structure-based pharmacophore was 
generated utilizing LigandScout 2.02 [34], which is based on a sophisticated ligand-protein complex 
interpretation algorithm. Two PLK1-ligand co-crystal structures (2YAC and 3KB7) [18,20] available 
were chosen. When creating pharmacophore model, the “Phase” mode was selected with waters and 
other heteroatom ignored due to their non-conservation in crystal circumstance. This produced two 
pharmacophore models. Considering that pharmacophore should contain the most common features 
and these two models indeed share some identical features, we compared and clustered them in 
Discovery Studio 2.5 to draw a new pharmacophore model. This model was eventually used to align Int. J. Mol. Sci. 2011, 12                 
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compounds in Discovery Studio 2.5, during which the conformations of compounds were generated 
with “best” option and the fitting method was “flexible” with the maximum omitted features of 3. 
3.3. CoMFA and CoMSIA Methodology 
The CoMFA and CoMSIA analyses were carried out with the RHEL 4.0 operating system using 
SYBYL 6.9. In CoMFA study, the aligned compounds were placed in the 3D cubic lattice with grid 
spacing of 2.0 Å. The standard CoMFA steric and electrostatic fields were calculated using a sp3 
carbon atom as steric probe and a +1 charge as electrostatic probe, with Lennard-Jones potential and 
the Coulombic potential, respectively. The cut off value for both fields was set to 30 kcal/mol and the 
minimum-sigma (column filtering) was set to be 2.0 kcal/mol to reduce the noise by omitting those 
lattice points. The five fields of CoMSIA (steric, electrostatic, hydrophobic, hydrogen bond donor and 
acceptor) were calculated for each lattice with a grid of 2 Å by employing a common probe atom with 
1 Å radius, +1 charge, and hydrophobic and hydrogen-bond property values of +1 [24]. The attenuation 
factor was set to the default value of 0.3 for the Gaussian function. 
3.4. Partial Least Squared (PLS) Analyses and Validation 
The relationship between the structures and the biological activities derived by the PLS algorithm. 
CoMFA and CoMSIA descriptors were used as independent variables and pIC50 values were used as 
dependent variables in PLS to generate corresponded 3D-QSAR model. The predictive ability of the 
models was evaluated by leave-one-out (LOO) algorithm, which gave the optimal number of 
component (ONC), the lowest standard error of prediction and cross-validation coefficient (q
2), 
calculated with Equation 1, 
q
2   
 



  2
mean exp
2
  exp pred
Y   Y
Y   Y
  1  (1)
where Ypred, Yexp and Ymean are the values (pIC50) of the predicted activity, experimental activity and 
mean activity for compounds in training set, respectively. 
The analysis of non-cross validation was performed to calculate the conventional r
2 using the ONC 
obtained from the LOO analysis. Validation of the utility of the model as a predictive tool was carried 
out by predicting the activity of an external test set of 21 compounds. The predictive r
2 ( r
2
pred), 
reflected the predictive power of the CoMFA and CoMSIA models, was calculated using Equation 2, 
 
2
pred exp Y Y     PRESS     
 
2
mean exp Y Y     SD     
r
2
pred
  SD PRESS 1   
(2)
where SD is the sum of the squared deviations between the experimental activities of the compounds 
in the test set and the mean activity of the compounds in the training set, PRESS is the sum of the 
squared deviations between predicted and experimental activities for every compound in the test set. Int. J. Mol. Sci. 2011, 12                 
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4. Conclusions 
The 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives are a class of novel, potent, selective 
and orally bioavailable PLK1 inhibitors with reasonable SAR and strong quantitative correlations. The 
CoMFA and CoMSIA studies were performed on these compounds based on three different alignment 
methods to build 3D-QSAR models. Most of the models showed good q
2 and r
2
pred values and revealed 
a good response to the test set validation. The CoMFA model generated from the 
pharmacophore-based method was found to be superior (model 2, q
2 = 0.628, r
2
pred = 0.785) to those 
obtained from GLIDE docking-based and common substructure based methods. All the CoMSIA 
models derived from three different alignment methods gave good results, whose q
2 and r
2
pred values 
were greater than 0.5 and 0.6, respectively. The q
2 value of the best CoMSIA model was only a little 
larger than that of other models. In view of that, three CoMSIA models were selected for further 
comparisons and analyses so that more valuable information for the structural requirements can be 
obtained. From our studies, it was found that the pharmacophore-based alignment produced the best 
model for CoMFA and the common structure-based alignment for CoMSIA. This indicated that the 
discovery of the optimal alignment method should depend on the statistical performances of 3D-QSAR 
models generated from the alignments based on those methods. In addition, suitable alignment 
methods for CoMFA and CoMSIA studies might be different. The comparative studies among the best 
CoMFA and the CoMSIA models were also demonstrated in the crystallographic environment of 
PLK1 and high consistency was found in steric, electrostatic and hydrogen bond donor fields. 
Furthermore, the contours of CoMSIA model 6 were compared with the structure-based 
pharmacophore model and the key factors related to binding affinity were reconfirmed. These 
satisfactory insights identified in the present study can be utilized to design and predict new potent 
compounds as PLK1 inhibitor candidates, and to discover compounds with novel scaffolds that can act 
as PLK1 inhibitors via similar mechanisms. 
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